Europe In-Vitro Diagnostics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Europe In-Vitro Diagnostics Market Trends and Insights

Growing Prevalence of Chronic and Infectious Diseases

Multimorbidity now impacts 50% of Europeans aged 65-74, rising from 44% in 2011, further widening the gap between life expectancy and healthy life years. The European Commission’s Safe Hearts Plan, targeting universal annual measurements of blood pressure, cholesterol, and blood sugar by 2035, is driving increased per-capita test volumes for HbA1c, lipid panels, cardiac biomarkers, and oncology markers^{[1]European Commission, “Safe Hearts Plan,” ec.europa.eu}. Infectious-disease surveillance remains a critical focus, with integrated molecular panels for HIV, hepatitis, respiratory viruses, and antimicrobial resistance profiling forming the backbone of routine hospital and public health operations. The launch of bioMérieux and Oxford Nanopore’s AmPORE-TB marks a strategic shift toward rapid sequencing for the characterization of drug-resistant tuberculosis. Sustained demand across chronic and infectious disease segments is expected to contribute an estimated 1.2-percentage-point increase to the CAGR of the Europe in-vitro diagnostics market.

Increasing Adoption of Point-of-Care Testing

With the expansion of hospital-at-home programs, point-of-care formats now contribute to over 30% of the in-vitro diagnostics market in Europe. England's virtual ward initiative, supported by a GBP 450 million investment through 2024, leverages near-patient testing to reduce emergency admissions. The FDA-cleared QIAstat-Dx mini panels, which deliver gastrointestinal reports within one hour, exemplify the adoption of user-friendly cartridges in primary care and pharmacy settings^{[2]QIAGEN, “QIAstat-Dx FDA Clearance Press Release,” qiagen.com}. Additionally, pharmacist-led testing, now authorized in 18 OECD countries, and nurse-managed remote-monitoring protocols are driving the decentralization of sample collection. Accelerating reimbursement frameworks are further fueling market growth, contributing to a 0.9-percentage-point CAGR increase in Europe's in-vitro diagnostics market.

Expansion of National Genomic Medicine Programs

France’s Plan France Médecine Génomique delivered 12,737 rare-disease and cancer reports by end-2023 with a 30.6% diagnostic yield, targeting 235,000 genomes annually by 2027. Germany’s genomDE integrates sequencing into routine oncology and rare-disease care under a unified national infrastructure. The UK NHS Genomic Medicine Service exceeded 810,000 genomic tests in 2024 and is embedding circulating-tumor-DNA assays across oncology pathways. Spain’s contribution to the Genome of Europe project underscores continental alignment. These initiatives collectively add 0.7-percentage-points to the Europe in-vitro diagnostics market growth curve as companion-diagnostic reimbursement and data-analysis capacity scale.

Digital Health Integration: Enhancing Remote Sample Collection and Result Delivery

Cloud-connected analyzers and GDPR-compliant laboratory information systems now transmit encrypted results to patient portals, supporting remote care models. The European Health Data Space sets interoperability rules for cross-border exchange, and the Safe Hearts Plan earmarks EUR 20 million for AI cardiovascular tools. CMS reimbursement for Illumina’s TruSight Oncology Comprehensive test at USD 2,989.55 signals payer acceptance of comprehensive genomic profiling in decentralized laboratories. Robust encryption, pseudonymization, and cybersecurity audits remain prerequisites for procurement, yet successful pilots contribute 0.6 percentage points to market CAGR.

Stringent and Lengthy Regulatory Approval Processes Under EU IVDR

Two-thirds of IVDs still awaited certification under the 2022 EU IVDR as of 2024, straining notified-body capacity and elongating time-to-market^{[3]European Commission, “IVDR Transition Status Update,” ec.europa.eu}. SMEs shoulder disproportionate documentation and clinical-evidence costs, risking market exits. A December 2025 European Commission proposal outlines accelerated pathways for breakthrough devices, yet relief will not materialize before 2027. The resulting bottleneck trims 0.8 percentage points from the Europe in-vitro diagnostics market CAGR in the short term.

Laboratory Workforce Shortages and Operational Constraints

Health-workforce aging parallels patient demographics. The European Commission-OECD Health at a Glance 2024 review urges increased training slots and retention incentives amid accelerating technologist retirements. Automation offsets some gaps, yet capital budgets and service-engineer availability limit adoption in smaller labs. Persistent staffing shortages depress throughput, stretching turnaround times and subtracting 0.4 percentage points from long-run Europe in-vitro diagnostics market expansion.

Segment Analysis

By Test Type: Molecular Diagnostics Gain Momentum

Clinical chemistry retained 32.12% of 2025 revenue, yet molecular diagnostics is forecast to expand fastest at 7.43% CAGR, lifting the Europe in-vitro diagnostics market size for sequencing consumables and bioinformatics. Companion diagnostic approvals for EGFR, RET, and NTRK mutations, combined with national sequencing subsidies, drive recurring demand for reagents. Rapid multiplex platforms such as QIAstat-Dx Rise, capable of 160 molecular tests daily, exemplify throughput gains needed to meet decentralized acute-care volumes. Routine biochemistry remains indispensable for chronic-disease management, anchoring base load in hospital labs.

Beyond infectious-disease panels, molecular assays are penetrating oncology, minimal residual disease monitoring, hereditary cancer screening, and pharmacogenomics. Illumina’s CMS-reimbursed TruSight Oncology Comprehensive workflow underscores payer confidence, smoothing adoption in regional centers. Genotype-guided drug dosing in cardiology and psychiatry is on reimbursement agendas in Germany and the Netherlands, setting the stage for further Europe in-vitro diagnostics market expansion.

Note: Segment shares of all individual segments available upon report purchase

By Product and Service: Software and Services Accelerate

Reagents and consumables captured 54.65% of 2025 revenue thanks to recurring kits for chemistry, immunoassay, and PCR workflows. Instrument fleets are entering a replacement cycle as labs favor modular, energy-efficient analyzers with middleware connectivity. Software and services will rise at an 8.11% CAGR as laboratories integrate AI interpretation, quality dashboards, and cybersecurity hardening.

The Europe in-vitro diagnostics market benefits from subscription models: pay-per-genome analytics, cloud LIS modules, and remote calibration services, all generating predictable annuities. Gentian Diagnostics’ 2026 partnership to co-develop a novel assay on an existing high-throughput chemistry line illustrates the asset-light route for smaller innovators to ride incumbent footprints.

By Usability: Disposables Still Dominate While Reusables Gain

Single-use strips, cassettes, and molecular cartridges held 67.43% share in 2025 because they eliminate cross-contamination risk and simplify regulatory clearance. Yet reusable analyzers, electrodes, and multi-test sensors are projected to climb 7.65% CAGR as sustainability procurement criteria tighten. EU Green Deal targets and hospital carbon accounting now reward durable platforms with recyclable consumables.

Hospital-at-home models, which revisit patients daily, prefer robust portable analyzers that amortize over multiple uses, a trend tilting future Europe in-vitro diagnostics market purchases toward reusables without displacing the entrenched dominance of disposables.

By Specimen Type: Blood Leads, Urine Rises

Blood and serum generated 48.23% of 2025 revenues, maintaining primacy in chemistry, hematology, immunoassay, and NGS workflows. Annual cholesterol and glucose screening targets under the Safe Hearts Plan preserve high-volume phlebotomy throughput. Urine testing, however, is forecast to rise 7.22% CAGR as home-based microalbumin, ketone, and pregnancy kits proliferate.

Saliva is carving niches in hormone and genetic testing; tissue biopsies remain oncology gold standards while liquid biopsies emerge for serial cancer monitoring. Non-invasive matrices broaden patient compliance, yet the Europe in-vitro diagnostics market continues to rely on venous draws for the majority of clinical actionable data.

Note: Segment shares of all individual segments available upon report purchase

By Application: Infectious Disease Tops, Diabetes Surges

Infectious-disease assays held 29.94% share in 2025, anchored by respiratory panels, HIV, and hepatitis screening, and antimicrobial-resistance detection. Diabetes applications, however, will grow fastest at 8.43% CAGR as continuous glucose monitors integrate with insulin-delivery systems and preventive screening intensifies. Oncology and cardiology benefit from genomic medicine and Safe Hearts milestones, respectively, expanding companion-diagnostic and lipid-panel volumes.

Autoimmune, nephrology, prenatal, and transfusion safety segments round out the Europe in-vitro diagnostics industry portfolio, each supported by guideline-driven testing cadences, yet none match the growth velocity of diabetes monitoring over the forecast window.

By End User: Home-Care and POC Centers Gain Traction

Diagnostic laboratories controlled 46.43% of 2025 revenues owing to centralized high-throughput capability, but home-care and point-of-care centers are projected to register an 8.54% CAGR, narrowing the gap. Hospital-at-home programs in France, Spain, and the UK depend on portable analyzers for bedside decisions. Pharmacy and nurse-led testing further decentralize access, positioning non-traditional settings as rising contributors to the Europe in-vitro diagnostics market size.

Hospitals retain complex assay dominance, whereas academic institutes drive NGS research and biomarker discovery. Survey data suggesting up to 25% of tests could migrate to homes by 2035 underscores the momentum behind decentralized care models.

Geography Analysis

Germany, with 24.76% revenue in 2025, leverages its large insured population, intensive care infrastructure, and genomDE precision-medicine investments to maintain its largest national share. High adoption of automation and antimicrobial-resistance protocols ensures steady instrument refresh cycles and reagent pull-through.

The United Kingdom will post the fastest 6.43% CAGR to 2031 as the NHS Genomic Medicine Service integrates circulating tumor DNA assays into standard oncology, streamlines procurement for validated tests, and expands virtual wards that rely on near-patient diagnostics. A post-Brexit regulatory pathway enabling rapid approvals for innovative devices further accelerates uptake.

France, Italy, and Spain together harness EU Recovery funds for personalized medicine and sequencing under the Genome of Europe umbrella, while Nordic nations emphasize digital interoperability and eco-friendly procurement, keeping the Europe in-vitro diagnostics market vibrant across disparate health-system models.